Morpholine as ubiquitous pharmacophore in medicinal chemistry: Deep insight into the structure-activity relationship (SAR)

2020 ◽  
Vol 96 ◽  
pp. 103578 ◽  
Author(s):  
Archana Kumari ◽  
Rajesh K. Singh
2017 ◽  
Vol 7 (2) ◽  
pp. 502-514 ◽  
Author(s):  
Lijun Yan ◽  
Yangyang Liu ◽  
Kaiwen Zha ◽  
Hongrui Li ◽  
Liyi Shi ◽  
...  

The structure–activity relationship of Nb modified SnO2–CeO2 catalysts was investigated for selective catalytic reduction of NO by NH3.


2017 ◽  
Vol 129 ◽  
pp. 218-250 ◽  
Author(s):  
Mohd. Javed Naim ◽  
Md. Jahangir Alam ◽  
Shujauddin Ahmad ◽  
Farah Nawaz ◽  
Neelima Shrivastava ◽  
...  

2018 ◽  
Vol 54 (27) ◽  
pp. 3351-3354 ◽  
Author(s):  
Xiaojun Su ◽  
Kaitlin M. McCardle ◽  
Julien A. Panetier ◽  
Jonah W. Jurss

A structure–activity relationship, revealed through a series of nickel-based CO2 reduction catalysts, provides insight into the role of redox-active macrocycles.


1996 ◽  
Vol 40 (3) ◽  
pp. 706-709 ◽  
Author(s):  
K M Slunt ◽  
J M Grace ◽  
T L Macdonald ◽  
R D Pearson

Mitonafide (4-nitro-benzoisoquinolinedione) and a number of structural analogs were synthesized and studied in order to determine the structural requirements for inhibition of leishmanial nuclear and kinetoplast topoisomerase II and human topoisomerase II. The structure-activity relationship studies with the mitonafide analogs demonstrated that there was selective targeting of leishmanial nuclear topoisomerase II and human topoisomerase II and differential targeting of kinetoplast over nuclear topoisomerase II in the parasite. Mitonafide analogs appeared to have multiple mechanisms of action leading to death of leishmanias, but several compounds that affected kinetoplast but not nuclear topoisomerase II were not cytotoxic as determined by short-term assays. These studies provide new insight into the differential sensitivities of leishmanial nuclear and kinetoplast topoisomerase II to topoisomerase II-targeting drugs.


Author(s):  
Bhupender Nehra ◽  
Bijo Mathew ◽  
Pooja A Chawla

Aim: To describe structure activity relationship of heterocyclic derivatives with multi-targeted anticancer activity. Objectives: With the following goals in mind, this review tries to describe significant recent advances in the medicinal chemistry of heterocycle-based compounds: (1) To shed light on recent literature focused on heterocyclic derivatives' anticancer potential; (2) To discuss recent advances in the medicinal chemistry of heterocyclic derivatives, as well as their biological implications for cancer eradication; (3) To summarise the comprehensive correlation of structure activity relationship (SAR) with pharmacological outcomes in cancer therapy. Background: Cancer remains one of the major serious health issues devastating the world today. Cancer is a complex disease in which improperly altered cells proliferate at an uncontrolled, rapid, and severe rate. Variables such as poor dietary habits, high stress, age, and smoking, can all contribute to the development of cancer. Cancer can affect almost any organ or tissue, although the brain, breast, liver, and colon are the most frequently affected organs. From several years, surgical operations and irradiation are in use along with chemotherapy as a primary treatment of cancer but still effective treatment of cancer remains a huge challenge. Chemotherapy is now one of the most effective strategies to eradicate cancer, although it has been shown to have a number of cytotoxic and unfavourable effects on normal cells. Despite all of these cancer treatments, there are several other targets for anticancer drugs. Cancer can be effectively eradicated by focusing on these targets, which include both cell-specific and receptor-specific targets such as tyrosine kinase receptors (TKIs). Heterocyclic scaffolds also have a variety of applications in drug development and are a common moiety in the pharmaceutical, agrochemical, and textile industries. Methods: The association between structural activity relationship data of many powerful compounds and their anticancer potential in vitro and in vivo has been studied. SAR of powerful heterocyclic compounds can also be generated using molecular docking simulations, as reported vastly in literature. Conclusions: Heterocycles have a wide range of applications, from natural compounds to synthesised derivatives with powerful anticancer properties. To avoid cytotoxicity or unfavourable effects on normal mammalian cells due to a lack of selectivity towards the target site, as well as to reduce the occurrence of drug resistance, safer anticancer lead compounds with higher potency and lower cytotoxicity are needed. This review emphasizes on design and development of heterocyclic lead compounds with promising anticancer potential.


Sign in / Sign up

Export Citation Format

Share Document